Triple negative breast cancer SABCS L. Dirix
|
|
- Jodie Fay Small
- 7 years ago
- Views:
Transcription
1 Triple negative breast cancer SABCS 2013 L. Dirix
2 Triple Negative Breast Cancer 20 % of invasive breast cancers ER, PR and HER2 negative More in A-A, Hispanics, younger and BRCA1 carriers Poor prognosis compared to ER+ or HER2+ Early recurrence, visceral and CNS relapse Median OS < 1 year in advanced disease % have basal-type expression profile
3 Semantics TN Basal-like : Perou-Sorlie terminology (derived from IDC) Myo-epithelial like (expressing epithelial and mesenchymal markers) -Tumours arising from these cells Defines a population of basal-cytokeratin expressing cells that may be found in either luminal of basal positions Triple negative (definitions based on negative observations should provoke some minor unrest) A lack of expression of both ER, PR and HER-2 Basal-like, TN and BRCA-ness are not synonymous but they do overlap substantially
4 Overall survival as a function of response to chemotherapy pcr v residual disease and TNBC v non-tnbc
5 Rates of breast-specific survival in triple-negative and other breast cancers
6 SABCS 2013 TNBC Triple negative subtyping TIL in TNBC CTC and DTC Mutational spectrum in TNBC Use of pre-operative chemotherapy Activity of chemo-therapeutics in TNBC in metastatic trials
7 Sub-types of triple negative breast cancer Evaluated gene expression profiles from 21 breast cancer data sets (14 training and 7 validation = 587 cases of TNBC) Used cluster analysis to sub-divide TNBC into 6 sub-types displaying unique gene expression and ontologies Identified breast cancer cells lines representative of each subtype Lehmann et al JCI 2011
8 Basal-like 1: cell cycle, DNA repair and proliferation genes Basal-like 2: Growth factor signaling (EGFR, MET, Wnt, IGF1R) IM: immune cell processes M: Cell motility and differentiation, EMT processes MSL: similar to M but growth factor signaling, low levels of proliferation genes (metaplastic cancers) Lehmann et al JCI 2011 LAR: Androgen receptor and downstream genes, luminal features
9 Sub-types demonstrate differential response to therapies in vivo Vehicle Cisplatin Anti-androgen P13K/mTOR inhibitor Lehmann et al JCI 2011
10 Tumor-Infiltrating Lymphocytes in the Breast Cancer Microenvironment in TNBC Tumour-infiltrating lymphocytes (TILs) NK cells, B cells (CD20+), T-Ly (CD3+) CD3+ either CD4+, CD8+, FOXP3+ ly (Treg) Distinction itil, stil, LPBC Indicator of good prognosis after chemotherapy; mainly in HER2+ and TNBC Predictor of response in PST SABCS 2013 Significantly associated with trastuzumab benefit Immune system enhances effectiveness of chemotherapy (drug and/or regimen specific?) Chemotherapy converts TIL- to TIL+, mainly increase in CD8+ SABCS 2013 GeparQuattro and FinHER trials assessing neoadjuvant trastuzumab in HER2+ BC GeparSixto phase II trial investigating addition of carboplatin to neoadjuvant therapy in HER2+ BC and TNBC ECOG 2197 and ECOG 1199 phase III trials exploring adjuvant therapy in TNBC
11 Prognostic significance of TIL in E 2197 and E 1199 N = 481 TNBC, Anthracycline based CT Endpoints DFS/OS/DRFI itil/stil/lpbc Pearson correlation: 0.79 for stil and 0.75 itil; 2 breast pathologists 80% have stil, 15% itil, LPBC in 4.4% Intratumoral Stromal Score N (%) N (%) (85) 95 (20) (12) 237 (49) 20 9 (2) 82 (17) 30 3 (<1) 37 (8) (2) 50 1 (<1) 9 (2) (2) Adams S, et al. SABCS Abstract S1-07..
12 ECOG 2197 and 1199: TILs in Adjuvant Therapy for TNBC Stromal TILs associated with better prognosis (DFS, DRFI, OS) after standard adjuvant therapy in TNBC (multivariate model) DFS HR: 0.84 (95% CI: ; P =.005) DRFI HR: 0.81 (95% CI: ; P =.02) OS HR: 0.79 (95% CI: ; P =.003) For every 10% incremental gain of stromal TILs: 14% reduction of risk for recurrence/death (P =.02) 18% reduction of risk for distant recurrence (P =.04) 19% reduction of risk for death (P =.01) Adams S, et al. SABCS Abstract S1-07..
13 SABCS
14 TIL in Geparsixto 2013
15 SABCS
16 GeparSixto: TILs for Carboplatin Neoadjuvant Tx for TN and HER2+ EBC Stromal TILs predictive of pcr to neoadjuvant chemotherapy in HER2+ and TN EBC 20-30% had LPBC and increased pcr (75% in Carbo arm) Stromal TILs are a continuous predictor of chemotherapy response Predictive effect particularly high in carboplatin arm: pcr increased from 34% to 75% Stromal TILs (per 10%) OR (95% CI) P Value Test for Interaction All patients PM 1.11 ( ) PM + carboplatin 1.35 ( ) <.0005 Triple negative PM 1.09 ( ) NS 0.27 PM + carboplatin 1.22 ( ).004 HER2+ PM 1.13 ( ) NS PM + carboplatin 1.53 ( ) <.0005 Denkert C, et al. SABCS Abstract S1-06..
17 Panitumumab + FEC100 + TXT N= 60 TNBC FEC100x4-TXT100x4 + anti-egfr Ab pcr 55.3% pcr related to high CD8+ TIL (p= ) pcr related to ratio CD8+/FOXP3+, > 1.23 (p= ) High pre-nact IGF-1R related to pcr Residual tumour in 17 cases : 9 high and increased HER3 and in 7/9 decreased Met 7 unchanged HER3, increased MET P /P
18
19 CTC in MBC CONSORT Letter of intent #2,400 potentially eligible pts in 18 centers Patients / Centres Call for data 1 center off study 2,174 pt data received Data cleaning 230 ineligible pts 1,944 individual patient data from 17 centers included
20 Results CTC at baseline 5 CTC / 7.5mL were detected in 47% of the 1,944 patients at baseline 1st quartile Median 3rd quartile Maximum 0 CTC 3 CTC 25 CTC CTC CTC count at baseline was associated with First line (N=1,110) All patients Performance status p< p< Liver metastases p< p< Bone metastases p< p< Elevated CEA p< p< Elevated CA15-3 p< p< Tumor subtype p=0.71 p< CTC HR+ 51% HER2+ 38% T. Neg 44%
21 Clinical Response by RECIST (%) Progression Free Progression Free Progression Free Progression Free Progression Free Progression Free Progression Free Progression Free ork City, NY, US, and San Antonio Johns Breast Cancer Hopkins Symposium- Sidney Cancer Therapy Kimmel and Research Comprehensive Center at UT Health Science Center-December Cancer 10-14, Center, 2013 Baltimore, MD, US, 2123 Significance of Circulating Tumor Cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (Nab-PAC) with or without the anti-death receptor 5 (DR5) Tigatuzumab (TBCRC 019) 1 Costanza Paoletti, 2 Yufeng Li, 1 Maria C. Muñiz, 1 Kelley M. Kidwell, 1 Kimberly Aung, 1 Dafydd G. Thomas, 1 Marty E. Brown, 3 Vandana Abramson, 4 William Irvin Jr., 5 Nancy Lin, 6 Minetta Liu, 7 Rita Nanda, 8 Julie Nangia, 9 Anna Maria Storniolo, 10 Tiffany Traina, 2 Christos Vaklavas, 1 Catherine Van Poznak, 11 Antonio C. Wolff, 2 Andres Forero, 1 Daniel F. Hayes on behalf of the TBCRC 1 Department of Internal Medicine Div Hem/Onc, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, US, 48105; 2 University of Alabama at Birmingham, Birmingham, AL, US, 35205; 3 Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN, US, 37204; 4 Bon Secours Cancer Institute, Midlothian, VA, US, 23114; 5 Dana-Farber Cancer Institute, Boston, MA, US, 02215; 6 Mayo Clinic, Rochester, MN, US, 55905; 7 University of Chicago, Chicago, IL, US, 60637; 8 Baylor College of Medicine, Houston, TX, US, 77030; 9 Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, US, 46202; 10 Memorial Sloan-Kettering Cancer Center, New York City, NY, US, and 11 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, US, s he e ve: ives: he CO CTC Materials and levels Methods ( 5 CTCs/7.5 Results ml) are Prognostic Conclusions (PFS) 2. CTC levels ( 5 CTCs/7.5 ml) are Prognostic (PFS) BLOOD FOR CTC EVALUATION CTC counts were determined in CTC VS. PFS 7.5 ml of CTC AT BASELINE ENUMERATION N= 52 DAY 15 N= 52 VS. DAY PFS 29 N= 49 whole blood (WB) using the Day 1 Day 15 Day 29 Logrank p = Logrank p = Logrank p = CXC Kit cycle 1 cycle 2 Using the AT 1 BASELINE 2 3 N= 52 CellSearch DAY 15 N= 52 assay, M-30 Ab Morphologi mo 3.3 mo Y/N pos Y/N cally 3.3 mo APOPTOSIS: apoptotic mo mo mo CTC Relative Y/N Evaluated using a <5CTCs (63.5%) compos M-30 PE <5CTCs (73.1%) ite staining monoclonal <5CTC (73.5%) Image antibody (M-30) 5CTCs (36.5%) 5CTCs (26.9%) 5CTCs (26.5%) (Peviva, Intact cell satisfying the Viable Y N N Stockholm, Category Figure related Description CTC Perfect event Apoptotic cells due to M-30 + Apoptotic cells due to M-30 + Morphologically apoptotic Morphologically apoptosis Cell Fragments Sweden) conjugated to phycoerythrin (PE) Visual inspection (nucleic condensation and/or fragmentation, as well as granular cytokeratin). This presentation is the intellectual property of the author/presenter. Contact them at pcostanz@umich.edu for permission to reprint and/or distribute. CTCs are elevated ( 5CTCs/7.5 ml) in 30-40% of TN MBC patients at baseline using CellSearch assay In this group of homogeneous prospectively enrolled patients, regardless of treatment, CTC levels reflected PFS and response Baseline Day 15 Day 29 No apparent: Interaction between CTCs and treatment arm Prognostic effect of CTC-Apoptosis Association between CTC-Apoptosis and response to tigatuzumab Logrank p cell = Logrank Months p = Months Logrank p = Months HR: 2.38 (95% CI: ) p=0.007 HR: 2.87 (95% CI: ) p=0.002 HR: 3.40 (95% CI: ) p=0.001 Early apoptotic Y Y N CTC 1 5 Nab-PAC Nab-PAC + Tig Baseline 61.5% 36.5% Months 31.6% 39.3% (32/52) (19/52) (6/19) (13/33) Day % (22/52) Day % (19/49) morphology features Intact cell satisfying the morphology features Nucleic condensation and or fragmentation 26.5% (14/52) 26.5% (13/49) Y Y N/Y Granular CK Y Y N/Y Nucleic condensation and or fragmentation Y N Y Granular CK Y N Y 15.8% (3/19) 22.2% (4/18) Early apoptotic CTC Early apoptotic CTC Late apoptotic event Late apoptotic event 33.3% (11/33) 29% (9/31) 3. No overall difference for PFS according to treatment arm AT BASELINE N= 52 Logrank p = <5CTCs nab-pac N=13 <5CTC nab-pac+ Tig N=20 CTC ENUMERATION VS. ORR 27/36 23/33 26/38 4. CTC-apoptosis is not more prognostic than CTC counts alone AT BASELINE N= 52 Logrank p = DAY 29 N= 49 FUTURE DIRECTIONS: ¾ Failure to clear CTCs might be used to direct patients onto novel/targeted trials ¾ In this trial, CTC Response ~ ORR: CTC response might be used as investigational endpoint in future Phase II trials Completely broken mo cells, but part of the N NA mo mo nucleus is still mo References surrounded by the CK mo mo 1.9 mo mo <5CTCs (63%) mo 5CTC nab- 5CTCs/ 25% Results <5CTCs (63.5%) apo (10%) 5CTCs/<25% apo (27%) PAC+ Tig N=13 1. CellSearch <5CTCs 0 (73.1%) CTCs Months Months <5CTC (73.5%) assay detects CTCs in TN MBC nab-pac N=6 Acknowledgements 5CTCs 5. High CTC levels predict lower chance of response 5 (36.5%) CTCs/7.5 ml WB CTCs/7.5 ml WB 5CTCs (26.9%) 5CTCs (26.5%) By Randomized Arm Cristofanilli M. et al. NEJM 2004; 2 Liedtke C et al. PPO Updat Prin Prac Oncol 2010; 3 Sieuwerts A.M. et al. JNCI 2009; 4 Buchsbaum D. et al. Clin Cancer Res 2003; 5 Smerage J.B. et al. Mol Oncol We are grateful to all the patients who generously volunteered to participate in this study. We thank the TBCRC investigators, research nurses, & study coordinators for their efforts on behalf of the patients We are appreciative of the funding support provided to the TBCRC by its three foundation partners: Months The AVON Foundation Months 7/19 The Breast Cancer Research Foundation 4/14 Susan G. Komen for the Cure HR: 2.38 (95% CI: ) p=0.007 HR: 2.87 (95% CI: ) p=0.002 HR: 2/13 We 3.40 thank Veridex/Janssen, (95% CI: LLC, ) Fashion Footwear Charitable p=0.001 Foundation of 3. No overall difference for PFS according to treatment arm Results New York/QVC Presents Shoes on Sale (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP) for their support. We thank the Susan G. Komen for the Cure and the Triple Negative Breast Cancer Foundation for the funding of the Promise Grant 4. CTC-apoptosis is not more prognostic than CTC counts alone AT BASELINE N= 52 AT BASELINE N= 52
22 Mutations and Protein Expression comparison between TN and non-tnbc in 5500 BCs ABCS 2013 O Shaughnessy et al. PD4-1, SABCS
23 Mutations and Protein Expression comparison between TN and non-tnbc in 5500 BCs AR is expressed in 50% of ER- HER2+ and 18% of TNBC Nearly all AR + cases have PI3KCA mutation or PTEN loss suggestive of pathway activation, Combined AR and PI3K inhibition should be evaluated In TNBC but not in ER+ or HER2+ disease, AR expression is associated with decreased Ki67. AR/Ki67 expression similar in primary versus metastatic cases. APC mutations occur in 5% of BC EGFR gene amplification occurs in about 10% of poor prognosis ER+ and 20% of ER- breast cancers O Shaughnessy et al. PD4-1, SABCS 2013
24 Mutations and Actionable Targets in TNBC Deep sequencing of residual disease in NAC treated TNBC N = 81, 182 oncogenes and tumour suppressor genes Mean depth of coverage was 635 ( ) JAK2 amplifications correlate with extreme poor prognosis JAK2 amplification correlates with EMT, TGF-beta and IL-6 overexpression 2013 SABCS 2013
25
26 NA Clinical Studies in TNBC Carboplatinum Bevacizumab Everolimus Eribulin Velaparib
27 SABCS 2013 Geparsixto
28 Neoadjuvant Chemo plus Carboplatin +/- Bevacizumab in Stage II-III TNBC (Open-Label Phase II CALGB 40603) Paclitaxel 80mg/m 2 wkly x4 ddac x4 Paclitaxel 80mg/m2 wkly x4 Bevacizumab 10mg/kg q2w x 9 Paclitaxel 80mg/m 2 wkly x4 Carboplatin AUC 6 q3w x 4 Paclitaxel 80mg/m 2 wkly x4 Bevacizumab 10mg/kg q2w x 9 Carboplatin AUC 6 q3w x 4 ddac x4 ddac x4 ddac x4 Surgery 4-8 wks after last ddac XRT No adjuvant chemo planned
29 Neoadjuvant Chemo plus Carboplatin +/- Bevacizumab in Stage II-III TNBC (Phase II CALGB 40603) ABCS 2013 SABCS 2013
30 Neoadjuvant Chemo plus Carboplatin +/- Bevacizumab in Stage II-III TNBC (Phase II CALGB 40603) SABCS 2013 SABCS 2013
31 Neoadjuvant Chemo plus Carboplatin +/- Bevacizumab in Stage II-III TNBC (Phase II CALGB 40603) pcr Breast No Carbo Carbo Bev Effect (ypt0/is N any), % (n = 212) (n = 221) No bev (n = 218) Bev (n = 215) Odds ratio: 1.58; P =.0089 Carbo effect 46 Odds ratio: 1.76; 60 P =.0018 Carbo/bev interaction P =.52 pcr Breast /Axilla (ypt0/is N0), % No Carbo (n = 212) Carbo (n = 221) Bev Effect No bev (n = 218) Bev (n = 215) Odds ratio: 1.36; P =.0570 Carbo effect 41 Odds ratio: 1.71; 54 P =.0029 Carbo/bev interaction P =.43 Sikov WM, et al. SABCS Abstract S5-01..
32 CALGB 40603: Safety Select Grade 3 AEs, % Chemo Chemo + Bev Chemo + Carbo Chemo + Carbo + Bev Neutropenia Thrombocytopenia Febrile neutropenia Hypertension * Nausea/vomiting Fatigue Treatment discontinued Serious AEs, n Total FN during AC Nausea/vomiting/dehydration Bleeding DVT or PE Infection (normal ANC) GI perforation *1 death due to uncontrolled hypertension. Sikov WM, et al. SABCS Abstract S5-01.
33 CALGB 40603: Conclusions Addition of bevacizumab increased pcr in breast but not in breast/axilla Increases in grade 3 hypertension, febrile neutropenia, serious infections, bleeding, thromboembolic and surgical complications Addition of carboplatin increased pcr in breast and breast/axilla Increases in grade 3/4 neutropenia, thrombocytopenia Also increased frequency of paclitaxel dose modifications pcr benefit independent of bevacizumab No interaction between bevacizumab and carboplatin for efficacy Sikov WM, et al. SABCS Abstract S5-01.
34 Bevacizumab in Advanced Triple Negative Breast Cancer Stage IV trial Regimen DFS HR (95% CI) ECOG 2100 Weekly Paclitaxel 0.54( ) AVADO Docetaxel 0.68( ) RIBBON-1 CT 0.72( ) Meta-analysis OS CT +/- Bev 0.96( ) Stage IV pretreated RIBBON-2 Chemo +/- Bev 0.494( ) RIBBON-2 OS 0.624( )
35 Bevacizumab in Neoadjuvant Triple Negative Breast Cancer Gepar Quinto Gepar Quinto NSABP- 40 NSABP- 40 CALGB CALGB CT CT + B CT CT+B CT CT+B N pcr breast % 51.5% 48% 59% pcr breast + LNN P=0.34 P= % 39.3% 23% 27.6% 44% 52% P=0.003 P=0.08 P=0.057
36 Cisplatin + Paclitaxel ± Everolimus in Patients With Stage II/III TNBC Randomized phase II trial Randomized 2:1 Patients with stage II-III TNBC; primary tumor > 1 cm (N = 145) Cisplatin + Paclitaxel + Everolimus Cisplatin + Paclitaxel + Placebo Surgery Cisplatin 25 mg/m 2 /wk for 12 wks; everolimus 5 mg/day for 12 wks; paclitaxel 80 mg/m 2 weekly for 11 wks starting on Wk 2. Mayer IA, et al. SABCS Abstract PD1-6.
37 Response, % Efficacy of Neoadjuvant Everolimus in Patients With TNBC 100 Chemo + everolimus Chemo + placebo pcr Near pcr No pcr Not Evaluable Mayer IA, et al. SABCS Abstract PD1-6.
38
39 Neoadjuvant Carboplatin and Eribulin Mesylate in Patients With Stage I-III TNBC Phase II trial of eribulin (1.4 or 1.1 mg/m 2 IV on Days 1, 8) + carboplatin (6 AUC IV on Day 1) every 3 wks for 8 cycles (N = 30) Total 4 cycles before surgery pcr primary endpoint (RCB secondary endpoint) Eribulin + carboplatin showed activity in TNBC Pathologic complete response: 43.3% (95% CI: ) Clinical response rate (CR + PR): 80% (95% CI: ) Response by RCB: RCB 0: 44.8%; RCB I: 0%; RCB II: 51.7%; RCB III: 3.5% Additional analysis suggested association between cytoplasmic CDK2 and pathologic complete response In vitro proliferation assays showed combination effect for eribulin + CDK inhibitor Eribulin and carboplatin showed significant activity and tolerability as neoadjuvant therapy for patients with TNBC Giordano S, et al. SABCS Abstract P
40 I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) schema. Esserman L J et al. JCO 2012;30:
41 RFS stratified by pcr for the overall population of patients by BC Subtype Esserman L J et al. JCO 2012;30:
42 2013
43 2013
44 I-SPY2: Neoadjuvant Veliparib/Carboplatin + Paclitaxel for Patients With High-Risk BC Veliparib: potent PARP inhibitor First efficacy results for 1 of 7 current experimental arms of the adaptive I-SPY 2 phase II trial Patients with HER2- BC randomized to veliparib + carboplatin + paclitaxel (n = 72) vs paclitaxel (n = 44), followed by 4 cycles AC prior to surgery Biomarker Subtype, % MP Hi-1 MP Hi-2 HR+ HR- HR+ HR- HER HER Rugo HS, et al. SABCS Abstract S5-02.
45 I-SPY2: Neoadjuvant Veliparib/Carboplatin + Paclitaxel for Patients With High-Risk BC
46 I-SPY2: Conclusions Adaptive trial design found veliparib/carboplatin treatment efficacious in patients with triple-negative breast cancer Trial not designed to evaluate individual contributions of veliparib and carboplatin Adverse events increased with veliparib/carboplatin regimen Toxicity may be managed with dose reductions and delay I-SPY2 trial design efficiently evaluated treatment regimen in patient subsets based on biomarker analysis Additional response predictors currently under investigation Rugo HS, et al. SABCS Abstract S5-02.
47 Enchant-1 Trial Ganetespib Hsp90 inhibitor 150 mg/sqm twice weekly iv 15 pts with TNBC 9 metabolic response 1 PR, 2 SD in 6 evaluable pts Awada et al, P
Progress in Treating Advanced Triple Negative Breast Cancer
Progress in Treating Advanced Triple Negative Breast Cancer Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Triple Negative Breast Cancer by Subtype
More informationJennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall
Jennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall Meeting September 26, 2015 To understand the biology and
More informationPersonalized Medicine for Triple Negative Breast Cancer - New Dimensions in Therapeutic Individualization
Personalized Medicine for Triple Negative Breast Cancer - New Dimensions in Therapeutic Individualization Bryan P. Schneider & Milan Radovich Medicine & Medical Molecular Genetics Indiana University School
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationNew Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationTriple negative Breast Cancer Patient
Triple negative Breast Cancer Patient Alison L Jones November 2013 Mrs Trisha Negative Aged 52) Diagnosed November 2001 T2 N1 (2/11)M0 Left breast. No family history WLE/ANC then FEC/T + RT Relapsed 2013
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationESMO 2014 Summary Breast Cancer
ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationNew developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough?
New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? F. Cardoso, MD Champalimaud Cancer Center Lisbon, Portugal BBM 2010 Thank you to A Tutt & PRIME Oncology
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationQu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationUpdate on neoadjuvant treatment of breast cancer
Update on neoadjuvant treatment of breast cancer «IS PATHOLOGIC COMPLETE RESPONSE STILL A GOOD SURROGATE OF SURVIVAL?» Complete histological response varies according to tumoral type pcr (%) 40 35 30 25
More informationAdjuvant Therapy with Trastuzumab
Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationMetastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.
TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationP! P! P! 2nd Mess! P! P! P! P! P! Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade
Vaccine-Associated! Sarcoma! Hemangiosarcoma! Mast Cell Tumor! Osteosarcoma! 10 11! Survival! Survival Migration/Invasion! Survival Migration/Invasion Angiogenesis! Survival Migration/Invasion Angiogenesis
More informationThe current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment
The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment Ahmad Awada, MD, PhD Head of Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationInflammatory Breast Cancer: A Unique Pathologic Entity?
Inflammatory Breast Cancer: A Unique Pathologic Entity? Sandra M. Swain, M.D. Director, Washington Cancer Institute Washington Hospital Center Washington DC Outline Overview Therapy High dose chemotherapy
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationAdvances in Neoadjuvant and Adjuvant Therapy
Advances in Neoadjuvant and Adjuvant Therapy Kathy S. Albain, MD, FACP Director, Breast Clinical Research Program Co-Director, Breast Oncology Center Director of the Thoracic Oncology Program Professor
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationNovel Targets in Breast Cancer. Vandana Abramson, MD May 1, 2010
Novel Targets in Breast Cancer Vandana Abramson, MD May 1, 2010 Disclosure Information I have no financial relationships to disclose relevant to the content of this presentation. Breast ca: many diseases
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationMetastatic Triple Negative Breast Cancer: Ongoing Trials. Joan Albanell Hospital del Mar, Barcelona
Metastatic Triple Negative Breast Cancer: Ongoing Trials Joan Albanell Hospital del Mar, Barcelona Metastatic Triple Negative Breast Cancer Spectrum Targeting Growth Factor Receptors Targeting Signaling
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationNOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationPI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationPrognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
Original Study Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy Sota Asaga, Takayuki Kinoshita, Takashi Hojo, Junko Suzuki, Kenjiro Jimbo, Hitoshi
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationPersonalized Predictive Medicine and Genomic Clinical Trials
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationIn treating triple negative breast cancer,
Treatment of triple negative breast cancer Triple negative breast cancers, as a subgroup, are associated with a poor prognosis. But different subtypes within triple negative disease are associated with
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSan Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 10 14, 2013
Final Analysis of a Phase II, 3-Arm, Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by 6 cycles of Docetaxel and Carboplatin with Trastuzumab
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More information